# DB-06 (NCT04494425)

> Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04494425
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Advanced or Metastatic Breast Cancer
- Interventions: Trastuzumab deruxtecan; Capecitabine; Paclitaxel; Nab-Paclitaxel
- Enrollment: 866
- Primary outcome: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population

## Commentary we found

- X threads: 167
- YouTube: 163
- Podcasts: 126
- X videos: 4

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=db-06-nct04494425

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04494425", "email": "<work email>"}; the inbox owner confirms by the emailed link.